Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.…
7,978€
4,12%
Echtzeit-Aktienkurs Rocket Pharmaceuticals
Bid:
Ask:
Nachrichten zur Rocket Pharmaceuticals Aktie
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain
…
Rocket Pharmaceuticals Q3 Earnings Beat, Pipeline in Focus
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.…
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
…
Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06%
The Global Regenerative Medicine Market Size was Valued at USD 31.90 Billion in 2023 and the Worldwide Regenerative Medicine Market…
Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
…
Rockets (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the…
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
…
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
…
Rocket Pharmaceuticals appoints Aaron Ondrey as CFO
…
Rocket Pharmaceuticals director sells over $7.79 million in company stock By Investing.com
Rocket Pharmaceuticals director sells over $7.79 million in company stock…
Rocket Pharmaceuticals executive sells over $69k in company stock By Investing.com
Rocket Pharmaceuticals executive sells over $69k in company stock…
Rocket Pharmaceuticals Promising Path In Gene Therapy
…
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Rocket Pharmaceuticals (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the…